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(52 strains, 49%), foLLowed by C. pampsilosis (26%) 
and C. slabmta (13%). A total of 55 (53%) of 104 
adult patients had received adequate antifunga[ 
treatment, of whom 43 (78%) were treated with 
fluconazoLe and eight (15%) with micafungin; on 
the other hand, 33 adults received no antifunga[ 
agent. In addition, 16 (15%)patients were treated 
with Low dosages of fluconazoLe. The overaLL mor- 
tality was 45%. MuLtivariate analysis indicated 
that prolonged hospital stay (P = 0.02; OR 2.95; CI 
1.14-7.62), central venous catheter-reLated infec- 
tion (P = 0.007; OR 3.40; CI 1.39-8.29) and inade- 
quate of antifunga[ treatment (P=0.03; OR 2.76; 
CI 1.09-6.99) were associated with candidemia- 
related death. The risk of death was similar in 
patients infected by C. albicans and those infected 
by non-aLbicans Candida spp. 
Conclusions: Candidemia is associated with a high 
mortality rate among criticaLLy iLL patients. In- 
creased awareness of risk factors and cLearLy de- 
fined infection control policies are needed to bet- 
ter address the problem of nosocomia[ Candida 
infections. 
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Introduction: Data on the use of caspofungin in 
combination with other systemic antifunga[ drugs 
for pediatric patients are scanty. 
Methods: A prospective study was performed from 
November 2002 to November 2005 to investigate 
the safety and efficacy of caspofungin-based com- 
bination therapy in children and adolescents. 
Results: Sixty-six patients were recruited with a 
median age at diagnosis of 11.3 years; most of 
them were affected by an underlying malignant 
disease. Twenty-one (32%) patients developed an 
invasive funga[ infection (IFI) after hematopoietic 
stem ceLL transplantation, 22 after primary diag- 
nosis, and 23 after relapse. Severe neutropenia 
was present in 52 (79%) patients. The mycoses 
were classified as possible in 17 (26%), probable 
in 20 (30%) and documented in 29 (44%) patients, 
respectively. A favorable response to antifunga[ 
therapy was obtained in 37 patients (56%) and the 
probability of 100-day survival was 72%. OveraLL, 
the combination therapy was weLL tolerated. After 
a median foLLow-up of 1.2 years, 31 patients were 
alive (47%). The probability of overaLL survival LOS) 
was significantly different for mycosis diagnosed 
after relapse, 20.9%, after HSCT, 32.4%, and after 
primary diagnosis, 48%, p 0.007. In a multivariate 
analysis, underlying disease status was the factor 
associated with favorable response, whilst factors 
associated with 100-day survival were the duration 
of therapy with caspofungin and the achievement 
of a favorable response; and those associated with 
OS were the occurrence of IFI after primary diag- 
nosis, use of surgery, and the achievement of a 
favorable response. 
Conclusion: This study showed that caspofungin- 
based combination antifunga[ therapy is an effica- 
cious therapeutic option for pediatric patients with 
invasive mycoses. These data need to be confirmed 
by prospective controLLed studies. 
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Background: RSV infection might be associated 
with high morbidity and mortality among immuno- 
compromised patients (pts). LittLe is known about 
the outcome of this infection in pts with Leukemia. 
Objectives: To evaluate the impact of antivi- 
ra[ therapy for RSV infection in patients with 
Leukemia. 
Materials & Methods: We reviewed the records of 
such pts seen at our institution between Oct 1999 
and Dec 2004 to determine the cLinicaL characteris- 
tics, risk factors, and outcome in Leukemia pts with 
RSV infection. 
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Results: Fifty-two pts with teukemia nd RSV in- 
fection were identified. The median age was 47y 
(1-83y). Most pts were mate (65%), and had acute 
teukemia (65%). Forty-six percent of pts had re- 
ceived satvage chemotherapy and most (62%) were 
on corticosteroids before RSV infection. Most pts 
(27, 52%) had pneumonia, and 25 (48%) had upper 
respiratory infection (URI). When compared to pts 
with URI, pts with pneumonia had tonger duration 
of symptoms (9 vs 20 d), tonger tength of stay (6 vs 
12d), higher need for intensive care (0% vs 26%), 
higher APACHE-II score (11 vs 16), and received 
more steroids within one month before infection 
(48% vs 74%) (att P < 0.05). Twenty-four of 52 (46%) 
pts were treated with aerosotized ribavirin (RBV). 
Progression to pneumonia was associated with tack 
of RBV therapy (96% of non treated pts progressed 
to pneumonia vs 68% of treated pts, P<0.01). 
Muttipte togistic regression anatysis identified high 
APACHE-II score and tack of RBV therapy as inde- 
pendent predictors of progression to pneumonia 
(P < 0.01 ).RSV-attributed mortatity was 10% (5 of 52 
pts) at 30 d. Risk factors for mortatity by univariate 
anatysis were age >65y, tonger duration of symp- 
toms before RSV diagnosis (14 vs 4d), APACHE-II 
score >15, presence of comorbidities, and progres- 
sion to pneumonia (att P < 0.05). 
Conclusion: Progression to RSV pneumonia in pts 
with teukemia is associated with considerabte mor- 
bidity and mortatity. Timety treatment with rib- 
avirin therapy might hatt such progression. 
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Background: Scedosporium apiospermum and 
prolificans are fungi of increasing ctinicat signif- 
icance. In the finat months of 2000, an increase 
in the number of Scedosporium isotates and the 
appearance of S. prolificans was noted at the Atfred 
Hospitat, a quaternary referrat university hospitat 
providing state-wide trauma, burns, cystic fibrosis, 
heart and tung transptant and HIV services. At 
this time a new buitding and car park were being 
constructed. 
Objectives: To describe the epidemiotogy, ctinicat 
features and outcome of patients infected with 
Scedosporium spp. 
Method: A review was performed of the records of 
att patients where Scedosporium spp. had been iso- 
tated between June 30th 1997 and December 31st 
2003. Between March 2001 and Juty 2002 envi- 
ronmentat samptes were cottected from common 
hospital public access areas within and adjacent to 
the construction site and from ward areas including 
corridors, nursing stations and patient rooms. 
Results: Throughout the period of the study 
S. apiospermum was isotated at a constant rate, 
with between three to six clinical isolates being ob- 
tained per year. Seasonal clustering was not noted. 
S. apiospermum was isotated predominantty from 
the respiratory tract of patients with underlying 
tung diseases (28/31) and resulted in one dissem- 
inated infection and death. In contrast, S. prolif- 
icans was isotated onty after November 1999 from 
28 patients. Att 8 patients with haematotogicat 
matignancy or haematopoetic stem cett transptant 
(HSCT) had invasive infection: 6 had fungemia 
or disseminated infection and 6 died from infec- 
tion. In 2 patients with haematotogicat matignancy, 
cotonization was fottowed by invasive infection. 
S. proli[-icans caused tocatty invasive infection in 3 
immunocompetent patients and was found in the 
respiratory tract of 17 patients with undertying 
respiratory disease (eg cystic fibrosis or after tung 
transptant), but resutted in no fungemia, dissem- 
ination or deaths in these settings. Two dusters 
of invasive infection occurred in autumn of 2001 
and 2003 during periods of hospitat buitding works 
that required deep excavation. Susceptibitity test- 
ing of four invasive S. proli[-icans isotates from 
HSCT recipients showed att isotates were resis- 
tant to amphotericin B, fluconazote, itraconazote, 
5-flucytosine and ketoconazote. Voriconazote MlCs 
ranged from 2 to 8mg/L, and terbinafine MlCs 
ranged from 1 to 4mg/L. In contrast S. apiosper- 
mum showed a tess resistant profite. 
Conclusion: Scedosporium apiospermum and pro- 
li[-icans demonstrated istinct ctinicat and epidemi- 
otogicat features. During the period of this review 
S. proli[-icans emerged as a major pathogen in atto- 
geneic HSCT recipients in both the earty and tate 
post-transptant period atthough no environmentat 
source was detected. 
